Interestingly, MYBL1 is part of a gene expression-based risk score in DLBCL [55], and it is included in outstanding molecular signatures developed for molecular subclassification in DLBCL [56, 57]. This evidence concerns the gene MYBL1 and diffuse large B-cell lymphoma.